Inhibition of PKM2 Enhances Sensitivity of Olaparib to Ovarian Cancer Cells and Induces DNA Damage

Poly (ADP-ribose) polymerase inhibitors (PARPi) have showed clinical benefit as maintenance therapy in advanced ovarian cancer by impairing the homologous recombination (HR) pathway. Pyruvate kinase M2 (PKM2), the significant cancer metabolic biomarker, integrates with DNA damage to directly promote...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Sichun, Li, Duo, Xiao, Di, Wu, Tianyu, Hu, Xin, Zhang, Yu, Deng, Jun, Long, Jing, Xu, Simeng, Wu, Jingtao, Li, Gaofeng, Peng, Mei, Yang, Xiaoping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898351/
https://www.ncbi.nlm.nih.gov/pubmed/35280680
http://dx.doi.org/10.7150/ijbs.62947

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898351/
https://www.ncbi.nlm.nih.gov/pubmed/35280680
http://dx.doi.org/10.7150/ijbs.62947

Ejemplares similares